Ana Claudia Ranucci Durante

Ms. Ana Claudia Ranucci Durante

Faculdade de Tecnologia de Sao Paulo
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Leonardo Lima FuscaldiLeonardo Lima Fuscaldi
Leonardo Lima Fuscaldi
Danielle Vieira SobralDanielle Vieira Sobral
Danielle Vieira Sobral
ADAna Claudia Ranucci Durante
Ana Claudia Ranucci Durante
FMFernanda F. Mendonça
Fernanda F. Mendonça
Ana Cláudia Camargo MirandaAna Cláudia Camargo Miranda
Ana Cláudia Camargo Miranda
MBMarycel Rosa Felisa Figols de Barboza
Marycel Rosa Felisa Figols de Barboza
Prostate-specific membrane antigen (PSMA) is a glycoprotein present in the prostate, that is overexpressed in prostate cancer (PCa). Recently, PSMA-directed radiopharmaceuticals have been developed, allowing the pinpointing of tumors with the Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) imaging techniques. The aim of the present work was to standardize and validate an automatic synthesis module-based radiolabeling protocol for [68Ga]Ga-PSMA-11, as well as to produce a radiopharmaceutical for PET imaging of PCa malignancies. [68Ga]Ga-PSMA-11 was evaluated to determine the radiochemical purity (RCP), stability in saline solution and serum, lipophilicity, affinity to serum proteins, binding and internalization to lymph node carcinoma of the prostate (LNCaP) cells, and ex vivo biodistribution in mice. The radiopharmaceutical was produced with an RCP of 99.06 ± 0.10%, which was assessed with reversed-phase high-performance liquid chromatography (RP-HPLC). The product was stable in saline solution for up to 4 h (RCP > 98%) and in serum for up to 1 h (RCP > 95%). The lipophilicity was determined as −3.80 ± 0.15, while the serum protein binding (SPB) was 8.5 and a tumor-to-blood ratio of >3.5. In conclusion, an automatic synthesis module-based radiolabeling protocol for [68Ga]Ga-PSMA-11 was standardized and the product was evaluated, thus verifying its characteristics for PET imaging of PCa tumors in a clinical environment.

5 February 2019 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ADAna Claudia Ranucci Durante
Ana Claudia Ranucci Durante
Danielle Vieira SobralDanielle Vieira Sobral
Danielle Vieira Sobral
Ana Cláudia Camargo MirandaAna Cláudia Camargo Miranda
Ana Cláudia Camargo Miranda
ÉAÉrika V. de Almeida
Érika V. de Almeida
Leonardo Lima FuscaldiLeonardo Lima Fuscaldi
Leonardo Lima Fuscaldi
LMLuciana Malavolta
Luciana Malavolta
Parkinson’s disease (PD) is a neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta, leading to alteration of the integrity of dopaminergic transporters (DATs). In recent years, some radiopharmaceuticals have been used in the clinic to evaluate the integrity of DATs. These include tropane derivatives such as radiolabeled β-CIT and FP-CIT with iodine-123 (123I), and TRODAT-1 with metastable technetium-99 (99mTc). Radiolabeling of β-CIT with radioactive iodine is based on electrophilic radioiodination using oxidizing agents, such as Chloramine T or Iodo-Gen®. For the first time, the present work performed a comparative study of the radiolabeling of β-CIT with iodine-131 (131I), using either Chloramine T or Iodo-Gen® as oxidizing agents, in order to improve the radiolabeling process of β-CIT and to choose the most advantageous oxidizing agent to be used in nuclear medicine. Both radiolabeling methods were similar and resulted in high radiochemical yield (> 95%), with suitable 131I-β-CIT stability up to 72 h. Although Chloramine T is a strong oxidizing agent, it was as effective as Iodo-Gen® for β-CIT radiolabeling with 131I, with the advantage of briefer reaction time and solubility in aqueous medium.

18 January 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Danielle Vieira SobralDanielle Vieira Sobral
Danielle Vieira Sobral
Leonardo Lima FuscaldiLeonardo Lima Fuscaldi
Leonardo Lima Fuscaldi
ADAna Claudia Ranucci Durante
Ana Claudia Ranucci Durante
FMFernanda F. Mendonça
Fernanda F. Mendonça
LOLarissa R. de Oliveira
Larissa R. de Oliveira
LMLuciana Malavolta
Luciana Malavolta
Radiolabeled peptides with high specificity for overexpressed receptors in tumor cells hold great promise for diagnostic and therapeutic applications. In this work, we aimed at comparing the radiolabeling efficiency and biological properties of two different RGD analogs: GRGDYV and GRGDHV, labeled with iodine-131 (131I) and technetium-99m-tricarbonyl complex [99mTc][Tc(CO)3]+. Additionally, we evaluated their interaction with the αvβ3 integrin molecule, overexpressed in a wide variety of tumors, including glioblastoma. Both peptides were chemically synthesized, purified and radiolabeled with 131I and [99mTc][Tc(CO)3]+ using the chloramine-T and tricarbonyl methodologies, respectively. The stability, binding to serum proteins and partition coefficient were evaluated for both radioconjugates. In addition, the binding and internalization of radiopeptides to rat C6 glioblastoma cells and rat brain homogenates from normal animals and a glioblastoma-induced model were assessed. Finally, ex vivo biodistribution studies were carried out. Radiochemical yields between 95–98% were reached for both peptides under optimized radiolabeling conditions. Both peptides were stable for up to 24 h in saline solution and in human serum. In addition, the radiopeptides have hydrophilic characteristics and a percentage of binding to serum proteins around 35% and 50% for the [131I]I-GRGDYV and [99mTc]Tc(CO)3-GRGDHV fragments, respectively. Radiopeptides showed the capacity of binding and internalization both in cell culture (C6) and rat brain homogenates. Biodistribution studies corroborated the results obtained with brain homogenates and confirmed the different binding characteristics due to the exchange of radionuclides and the presence of the tricarbonyl complex. Thereby, the results showed that both radiopeptides might be considered for future clinical applications.

1 January 2019 in Brazilian Archives of Biology and Technology
Verified
Journal Article
Open access
PDF file
Ana Cláudia Camargo MirandaAna Cláudia Camargo Miranda
Ana Cláudia Camargo Miranda
ADAna Claudia Ranucci Durante
Ana Claudia Ranucci Durante
Leonardo Lima FuscaldiLeonardo Lima Fuscaldi
Leonardo Lima Fuscaldi
MBMarycel Rosa Felisa Figols de Barboza
Marycel Rosa Felisa Figols de Barboza
To present optimized chromatographic systems for radiochemical purity (RCP) evaluation of 99mTc-eluate and 99mTc-radiopharmaceuticals, as well as to assess doses calibrator reliability for routine purposes in hospital radiopharmacies. RCP was determined by different systems and radioactivity was quantified by TLC-scanner, doses calibrator and gamma-counter. Suitable and optimized systems were presented for RCP analyses. No significant differences were observed between radioactivity counting devices and, thus, doses calibrator showed reliability for RCP determination in hospital radiopharmacies.